IOVA Q3 2025 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M+15.2% YoY

Gross Profit

$66M97.9% margin

Operating Income

-$95M-140.7% margin

Net Income

-$91M-135.3% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+12.5%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$90M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$905M

Total Liabilities

$203M

Stockholders' Equity

$702M

Cash & Equivalents

$158M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$59M	+15.2%
Gross Profit	$66M	$19M	+252.6%
Operating Income	-$95M	-$89M	-6.6%
Net Income	-$91M	-$84M	-9.2%

Geographic Segments

UNITED STATES

$66M98%

Non-US

$1M2%